Effect of Lipoteichoic Acid on Dermal Vascular Permeability in Mice1

  1. Keiji Wada,
  2. Emiko Fujii,
  3. Hiroyasu Ishida,
  4. Toshimasa Yoshioka and
  5. Takamura Muraki
  1. Department of Pharmacology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

    Abstract

    Lipoteichoic acid (LTA), the cell wall component of Gram-positive bacteria, has been shown to cause inflammatory responses comparable to lipopolysaccharide (LPS) of Gram-negative bacteria. This study examined the activity of LTA to induce dermal microvascular permeability changes in mice. Vascular permeability was assessed by extravasation of Pontamine sky blue. Subcutaneous injection of LTA (200–400 μg/site) in mice that were preinjected i.v. with the dye increased local dye leakage in the skin at 1 to 3 h. The LTA-induced dye leakage was inhibited by indomethacin, valeryl salicylate, diphenhydramine, and a platelet-activating factor antagonist but not by inhibitors of nitric-oxide synthase, cyclooxygenase-2, or guanylate cyclase or by antibodies against tumor necrosis factor-α or interleukin-1α. LTA induced comparable increases in dye leakage in inducible nitric-oxide synthase-deficient mice and wild-type controls. Pretreatment of normal mice with i.v. LTA did not confer tolerance to LTA- or LPS-induced dye leakage. In contrast, systemic LPS administration induced tolerance against subsequent challenge with LPS but not LTA. Serum corticosterone levels, which were suggested to induce tolerance, were not increased by LTA pretreatment but were increased by LPS. Thus, LTA increases dermal microvascular permeability in mice. Among the inflammatory mediators, eicosanoids, platelet-activating factor, and histamine mediate the effect of both LTA and LPS, whereas nitric oxide, tumor necrosis factor-α, and interleukin-1α may not play a major role in LTA-induced dye leakage. The difference between LTA and LPS to stimulate corticosterone may partially explain the failure of LTA to induce tolerance against vascular dye leakage.

    Footnotes

    • Send reprint requests to: Dr. Keiji Wada, Department of Pharmacology, Tokyo Women's Medical University, School of Medicine, 8-1, Kawada-cho Shinjuku-ku, Tokyo 162-8666 Japan. E-mail:wada-kj{at}pop12.odn.ne.jp

    • 1 This study was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture, Japan (10672158, 09672336).

    • Abbreviations:
      LPS
      lipopolysaccharide
      LTA
      lipoteichoic acid
      NO
      nitric oxide
      iNOS
      inducible NO synthase
      PAF
      platelet-activating factor
      COX
      cyclooxygenase
      l-NAME
      NG-nitro-l-arginine methyl ester
      PG
      prostaglandin
      LY83583
      6-amino-5,8-quinolinedione
      TCV309
      3-bromo-5-[N-phenyl-N-[2-[[2-(1,2,3,4-tetrahydro-2-isoquinolyl-cabonyloxy)-ethyl]carbamoyl]ethyl]carbamoyl]-1-propylpyridinium nitrate
      NS-398
      N-(2-cyclohexyloxy-4-nitrophenyl)- methanesulphonamide
      WEB2086
      3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f]-[1,2,4]triazolo-[4,3-a][1,4]-diazepine-2-yl]-1-(4-morphonilyl)-1-propanone
      WEB2170
      6-(2-chlorophenyl)-8,9-dihydro-1-methyl-8-(4-morphonilyl)carbonyl-4H,7H-cyclopenta[4,5]thieno[3,5-f][1,2,4]triazolo[4,3-a][1,4]diazepine
      TLR
      Toll-like receptor
      TNF
      tumor necrosis factor
      IL
      interleukin
      PSB
      Pontamine sky blue
      • Received December 8, 1999.
      • Accepted March 27, 2000.
    « Previous | Next Article »Table of Contents